The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoring

Journal of Biomedicine and Biotechnology

Volumn 2011, Issue , 2011, Pages

  Schlom, Jeffrey ^a   Vergati, Matteo ^a   Tsang, Kwong Y ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2 RECEPTOR ALPHA; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR FOXP3; ZOLEDRONIC ACID;

ADVANCED CANCER; BONE MARROW CELL; BONE METASTASIS; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL FUNCTION; CELL MATURATION; CELL POPULATION; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; NEOPLASM; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; ARTICLE; CYTOLOGY; IMMUNE SYSTEM; IMMUNOLOGICAL MONITORING; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; MACROPHAGE;

CANCER VACCINES; HUMANS; IMMUNE SYSTEM; IMMUNE TOLERANCE; IMMUNOTHERAPY; MACROPHAGES; MONITORING, IMMUNOLOGIC; T-LYMPHOCYTES, REGULATORY;

EID: 79952215950     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2011/182413     Document Type: Review

References (80)

1. Kantoff P. W., Higano C. S., Shore N. D., Berger E. R., Small E. J., Penson D. F., Redfern C. H., Ferrari A. C., Dreicer R., Sims R. B., Xu Y., Frohlich M. W., Schellhammer P. F., Sipuleucel-T immunotherapy for castration-resistant prostate cancer New England Journal of Medicine 2010 363 5 411 422
2. Palena C., Abrams S. I., Schlom J., Hodge J. W., Cancer vaccines: preclinical studies and novel strateg (Pubitemid 44066525)
3. Palena C., Schlom J., Vaccines against human carcinomas: strategies to improve antitumor immune responses Journal of Biomedicine and Biotechnology 2010 2010
4. Gershon R. K., Kondo K., Cell interactions in the induction of tolerance: the role of thymic lymphocytes Immunology 1970 18 5 723 737
5. Gershon R. K., Kondo K., Infectious immunological tolerance Immunology 1971 21 6 903 914
6. Gershon R. K., Cohen P., Hencin R., Liebhaber S. A., Suppressor T cells Journal of Immunology 1972 108 3 586 590
7. Corthay A., How do regulatory T cells work? Scandinavian Journal of Immunology 2009 70 4 326 336
8. Floess S., Freyer J., Siewert C., Baron U., Olek S., Polansky J., Schlawe K., Chang H. D., Bopp T., Schmitt E., Klein-Hessling S., Serfling E., Hamann A., Huehn J., Epigenetic control of the foxp3 locus in regulatory T cells PLoS Biology 2007 5 2 e38
9. Sakaguchi S., Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T., Regulatory T cells: how do they suppress immune responses? International Immunology 2009 21 10 1105 1111
10. Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T., Miyara M., Fehervari Z., Nomura T., Sakaguchi S., CTLA-4 control over Foxp3 regulatory T cell function Science 2008 322 5899 271 275
11. Hodi F. S., Mihm M. C., Soiffer R. J., Haluska F. G., Butler M., Seiden M. V., Davis T., Henry-Spires R., MacRae S., Willman A., Padera R., Jaklitsch M. T., Shankar S., Chen T. C., Korman A., Allison J. P., Dranoff G., Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients Proceedings of the National Academy of Sciences of the United States of America 2003 100 8 4712 4717 (Pubitemid 36457795)
12. Phan G. Q., Yang J. C., Sherry R. M., Hwu P., Topalian S. L., Schwartzentruber D. J., Restifo N. P., Haworth L. R., Seipp C. A., Freezer L. J., Morton K. E., Mavroukakis S. A., Duray P. H., Steinberg S. M., Allison J. P., Davis T. A., Rosenberg S. A., Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma Proceedings of the National Academy of Sciences of the United States of America 2003 100 14 8372 8377 (Pubitemid 36842552)
13. Ribas A., Camacho L. H., Lopez-Berestein G., Pavlov D., Bulanhagui C. A., Millham R., Comin-Anduix B., Reuben J. M., Seja E., Parker C. A., Sharma A., Glaspy J. A., Gomez-Navarro J., Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206 Journal of Clinical Oncology 2005 23 35 8968 8977 (Pubitemid 46217464)
14. Camacho L. H., Antonia S., Sosman J., Kirkwood J. M., Gajewski T. F., Redman B., Pavlov D., Bulanhagui C., Bozon V. A., Gomez-Navarro J., Ribas A., Phase I/II trial of tremelimumab in patients with metastatic melanoma Journal of Clinical Oncology 2009 27 7 1075 1081
15. Hodge J. W., Chakraborty M., Kudo-Saito C., Garnett C. T., Schlom J., Multiple costimulatory modalities enhance CTL avidity Journal of Immunology 2005 174 10 5994 6004 (Pubitemid 40663786)
16. Chakraborty M., Schlom J., Hodge J. W., The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses Cancer Immunology, Immunotherapy 2007 56 9 1471 1484 (Pubitemid 47024711)
17. Peggs K. S., Quezada S. A., Chambers C. A., Korman A. J., Allison J. P., Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies Journal of Experimental Medicine 2009 206 8 1717 1725
18. Beyer M., Kochanek M., Darabi K., Popov A., Jensen M., Endl E., Knolle P. A., Thomas R. K., Von Bergwelt-Baildon M., Debey S., Hallek M., Schultze J. L., Reduced frequencies and suppressive function of CD4 + CD25 + regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine Blood 2005 106 6 2018 2025 (Pubitemid 41291715)
19. Motta M., Rassenti L., Shelvin B. J., Lerner S., Kipps T. J., Keating M. J., Wierda W. G., Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia Leukemia 2005 19 10 1788 1793 (Pubitemid 41486157)
20. Yang Z. Z., Novak A. J., Stenson M. J., Witzig T. E., Ansell S. M., Intratumoral CD4 + CD25 + regulatory T-cell-mediated suppression of infiltrating CD4 + T cells in B-cell non-Hodgkin lymphoma Blood 2006 107 9 3639 3646
21. Woo E. Y., Chu C. S., Goletz T. J., Schlienger K., Yeh H., Coukos G., Rubin S. C., Kaiser L. R., June C. H., Regulatory CD4 + CD25 + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer Cancer Research 2001 61 12 4766 4772 (Pubitemid 32691889)
22. Li L., Chao Q. G., Ping L. Z., Xue C., Xia Z. Y., Qian D., Shi-Ang H., The prevalence of FOXP3 regulatory T-cells in peripheral blood of patients with NSCLC Cancer Biotherapy and Radiopharmaceuticals 2009 24 3 357 367
23. Karagoz B., Bilgi O., Gumus M., CD8 + CD28-cells and CD4 + CD25 + regulatory T cells in the peripheral blood of advanced stage lung cancer patients Medical Oncology 2010 27 1 29 33
24. Javia L. R., Rosenberg S. A., CD4 + CD25 + suppressor lymphocytes in the circulation of patients immunized against melanoma antigens Journal of Immunotherapy 2003 26 1 85 93 (Pubitemid 36056828)
25. Sasada T., Kimura M., Yoshida Y., Kanai M., Takabayashi A., CD4 + CD25 + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression Cancer 2003 98 5 1089 1099 (Pubitemid 37022112)
26. Shen L. S., Wang J., Shen D. F., Yuan X. L., Dong P., Li M. X., Xue J., Zhang F. M., Ge H. L., Xu D., CD4 + CD25 + CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression Clinical Immunology 2009 131 1 109 118
27. Curiel T. J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J. R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M. L., Knutson K. L., Chen L., Zou W., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nature Medicine 2004 10 9 942 949 (Pubitemid 39273735)
28. Schaefer C., Kim G. G., Albers A., Hoermann K., Myers E. N., Whiteside T. L., Characteristics of CD4 + CD25 + regulatory T cells in the peripheral circulation of patients with head and neck cancer British Journal of Cancer 2005 92 5 913 920 (Pubitemid 40462639)
29. Ormandy L., Hillemann T., Wedemeyer H., Manns M. P., Greten T. F., Korangy F., Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma Cancer Research 2005 65 6 2457 2464 (Pubitemid 40490158)
30. DeLong P., Carroll R. G., Henry A. C., Tanaka T., Ahmad S., Leibowitz M. S., Sterman D. H., June C. H., Albelda S. M., Vonderheide R. H., Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma Cancer Biology and Therapy 2005 4 3 342 346 (Pubitemid 41351297)
31. Liyanage U. K., Moore T. T., Joo H. G., Tanaka Y., Herrmann V., Doherty G., Drebin J. A., Strasberg S. M., Eberlein T. J., Goedegebuure P. S., Linehan D. C., Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma Journal of Immunology 2002 169 5 2756 2761 (Pubitemid 34921025)
32. Miller A. M., Lundberg K., zenci V., Banham A. H., Hellstrm M., Egevad L., Pisa P., CD4 + CD25 + T cells are enriched in the tumor and peripheral blood of prostate cancer patients Journal of Immunology 2006 177 10 7398 7405 (Pubitemid 44715110)
33. Yokokawa J., Cereda V., Remondo C., Gulley J. L., Arlen P. M., Schlom J., Tsang K. Y., Enhanced functionality of CD4 + CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer Clinical Cancer Research 2008 14 4 1032 1040 (Pubitemid 351302548)
34. Dannull J., Su Z., Rizzieri D., Yang B. K., Coleman D., Yancey D., Zhang A., Dahm P., Chao N., Gilboa E., Vieweg J., Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells Journal of Clinical Investigation 2005 115 12 3623 3633 (Pubitemid 43121851)
35. Morse M. A., Hobeika A. C., Osada T., Serra D., Niedzwiecki D., Kim Lyerly H., Clay T. M., Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines Blood 2008 112 3 610 618
36. Rech A. J., Vonderheide R. H., Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells Annals of the New York Academy of Sciences 2009 1174 99 106
37. Mougiakakos D., Johansson C. C., Trocme E., All-Ericsson C., Economou M. A., Larsson O., Seregard S., Kiessling R., Intratumoral forkhead box p3-positive regulatory t cells predict poor survival in cyclooxygenase-2-positive uveal melanoma Cancer 2010 116 9 2224 2233
38. Zhou J., Ding T., Pan W., Zhu L. Y., Li A., Zheng L., Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients International Journal of Cancer 2009 125 7 1640 1648
39. Suzuki H., Chikazawa N., Tasaka T., Wada J., Yamasaki A., Kitaura Y., Sozaki M., Tanaka M., Onishi H., Morisaki T., Katano M., Intratumoral CD8 T/FOXP3 cell ratio is a predictive marker for survival in patients with colorectal cancer Cancer Immunology, Immunotherapy 2010 59 5 653 661
40. Halabi S., Small E. J., Kantoff P. W., Kattan M. W., Kaplan E. B., Dawson N. A., Levine E. G., Blumenstein B. A., Vogelzang N. J., Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer Journal of Clinical Oncology 2003 21 7 1232 1237 (Pubitemid 46606398)
41. Gulley J. L., Arlen P. M., Madan R. A., Tsang K. Y., Pazdur M. P., Skarupa L., Jones J. L., Poole D. J., Higgins J. P., Hodge J. W., Cereda V., Vergati M., Steinberg S. M., Haiabi S., Jones E., Chen C., Parnes H., Wright J. J., Dahut W. L., Schlom J., Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer Cancer Immunology, Immunotherapy 2010 59 5 663 674
42. Vergati M., Cereda V., Madan R., Circulating regulatory T-cell function and overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients treated with poxviral-based vaccine Proceedings of the International Society for Biological Therapy of Cancer 24th Annual Meeting October 2009 Washington, DC, USA
43. Kao J., Ko E. C., Eisenstein S., Sikora A. G., Fu S., Chen S. H., Targeting immune suppressing myeloid-derived suppressor cells in oncology Critical Reviews in Oncology/Hematology 2011 77 1 12 19
44. Delano M. J., Scumpia P. O., Weinstein J. S., Coco D., Nagaraj S., Kelly-Scumpia K. M., O'Malley K. A., Wynn J. L., Antonenko S., Al-Quran S. Z., Swan R., Chung C. S., Atkinson M. A., Ramphal R., Gabrilovich D. I., Reeves W. H., Ayala A., Phillips J., LaFace D., Heyworth P. G., Clare-Salzler M., Moldawer L. L., MyD88-dependent expansion of an immature GR-1 CD11b population induces T cell suppression and Th2 polarization in sepsis Journal of Experimental Medicine 2007 204 6 1463 1474 (Pubitemid 46919883)
45. Goni O., Alcaide P., Fresno M., Immunosuppression during acute Trypanosoma cruzi infection: Involvement of Ly6G (Gr1)CD11b immature myeloid suppressor cells International Immunology 2002 14 10 1125 1134 (Pubitemid 35175220)
46. Sunderktter C., Nikolic T., Dillon M. J., Van Rooijen N., Stehling M., Drevets D. A., Leenen P. J. M., Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response Journal of Immunology 2004 172 7 4410 4417 (Pubitemid 38375256)
47. Zhu B., Bando Y., Xiao S., Yang K., Anderson A. C., Kuchroo V. K., Khoury S. J., CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis Journal of Immunology 2007 179 8 5228 5237
48. Peranzoni E., Zilio S., Marigo I., Dolcetti L., Zanovello P., Mandruzzato S., Bronte V., Myeloid-derived suppressor cell heterogeneity and subset definition Current Opinion in Immunology 2010 22 2 238 244
49. Ostrand-Rosenberg S., Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity Cancer Immunology, Immunotherapy 2010 59 1593 1600
50. Rodriguez P. C., Quiceno D. G., Ochoa A. C., L-arginine availability regulates T-lymphocyte cell-cycle progression Blood 2007 109 4 1568 1573 (Pubitemid 46239590)
51. Hoechst B., Ormandy L. A., Ballmaier M., Lehner F., Krger C., Manns M. P., Greten T. F., Korangy F., A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4 + CD25 + Foxp3 + T cells Gastroenterology 2008 135 1 234 243 (Pubitemid 351899008)
52. Hoechst B., Voigtlaender T., Ormandy L., Gamrekelashvili J., Zhao F., Wedemeyer H., Lehner F., Manns M. P., Greten T. F., Korangy F., Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor Hepatology 2009 50 3 799 807
53. Huang B., Pan P. Y., Li Q., Sato A. I., Levy D. E., Bromberg J., Divino C. M., Chen S. H., Gr-1 + CD115 + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host Cancer Research 2006 66 2 1123 1131 (Pubitemid 43165981)
54. Serafini P., Mgebroff S., Noonan K., Borrello I., Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells Cancer Research 2008 68 13 5439 5449
55. Srivastava M. K., Sinha P., Clements V. K., Rodriguez P., Ostrand-Rosenberg S., Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine Cancer Research 2010 70 1 68 77
56. Gabrilovich D. I., Nagaraj S., Myeloid-derived suppressor cells as regulators of the immune system Nature Reviews Immunology 2009 9 3 162 174
57. Filipazzi P., Valenti R., Huber V., Pilla L., Canese P., Iero M., Castelli C., Mariani L., Parmiani G., Rivoltini L., Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine Journal of Clinical Oncology 2007 25 18 2546 2553 (Pubitemid 47041228)
58. Gustafson M. P., Lin Y., New K. C., Systemic immune suppression in glioblastoma: the interplay between CD14 + HLA-DRlo/neg monocytes, tumor factors, and dexamethasone Neuro-Oncology 2010 12 7 631 644
59. Vuk-Pavlovic S., Bulur P. A., Lin Y., Qin R., Szumlanski C. L., Zhao X., Dietz A. B., Immunosuppressive CD14HLA-DR monocytes in prostate cancer Prostate 2010 70 4 443 455
60. Diaz-Montero C. M., Salem M. L., Nishimura M. I., Garrett-Mayer E., Cole D. J., Montero A. J., Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy Cancer Immunology, Immunotherapy 2009 58 1 49 59
61. Ko J. S., Zea A. H., Rini B. I., Ireland J. L., Elson P., Cohen P., Golshayan A., Rayman P. A., Wood L., Garcia J., Dreicer R., Bukowski R., Finke J. H., Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients Clinical Cancer Research 2009 15 6 2148 2157
62. Kodumudi K. N., Woan K., Gilvary D. L., Sahakian E., Wei S., Djeu J. Y., A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers Clinical Cancer Research 2010 16 18 4583 4594
63. Guruvayoorappan C., Tumor versus tumor-associated macrophages: how hot is the link? Integrative Cancer Therapies 2008 7 2 90 95 (Pubitemid 351806535)
64. Liao D., Luo Y., Markowitz D., Xiang R., Reisfeld R. A., Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model PLoS One 2009 4 11
65. Koide N., Nishio A., Sato T., Sugiyama A., Miyagawa S. I., Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus American Journal of Gastroenterology 2004 99 9 1667 1674 (Pubitemid 39237489)
66. Hanada T., Nakagawa M., Emoto A., Nomura T., Nasu N., Nomura Y., Prognostic value of tumor-associated macrophage count in human bladder cancer International Journal of Urology 2000 7 7 263 269 (Pubitemid 30440592)
67. Lissbrant I. F., Stattin P., Wikstrom P., Damber J. E., Egevad L., Bergh A., Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival International Journal of Oncology 2000 17 3 445 451
68. Ohno S., Ohno Y., Suzuki N., Kamei T., Koike K., Inagawa H., Kohchi C., Soma G. I., Inoue M., Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer Anticancer Research 2004 24 5 3335 3342 (Pubitemid 39390949)
69. Leek R. D., Harris A. L., Tumor-associated macrophages in breast cancer Journal of Mammary Gland Biology and Neoplasia 2002 7 2 177 189 (Pubitemid 38420774)
70. Zhang B. C., Gao J., Wang J., Rao Z. G., Wang B. C., Gao J. F., Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma. Medical Oncology, 2010. Epub ahead of print
71. Leek R. D., Hunt N. C., Landers R. J., Lewis C. E., Royds J. A., Harris A. L., Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer Journal of Pathology 2000 190 4 430 436 (Pubitemid 30163582)
72. Orre M., Rogers P. A. W., Macrophages and microvessel density in tumors of the ovary Gynecologic Oncology 1999 73 1 47 50 (Pubitemid 29177598)
73. Leek R. D., Landers R. J., Harris A. L., Lewis C. E., Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast British Journal of Cancer 1999 79 5-6 991 995 (Pubitemid 29082138)
74. Nishie A., Ono M., Shono T., Fukushi J., Otsubo M., Onoue H., Ito Y., Inamura T., Ikezaki K., Fukui M., Iwaki T., Kuwano M., Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas Clinical Cancer Research 1999 5 5 1107 1113 (Pubitemid 29233226)
75. Gnant M., Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials Current Cancer Drug Targets 2009 9 7 824 833
76. Neville-Webbe H. L., Gnant M., Coleman R. E., Potential anticancer properties of bisphosphonates Seminars in Oncology 2010 37 supplement 1 S53 S65
77. Veltman J. D., Lambers M. E. H., Van Nimwegen M., Hendriks R. W., Hoogsteden H. C., Hegmans J. P. J. J., Aerts J. G. J. V., Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma British Journal of Cancer 2010 103 5 629 641
78. Vergati M., Intrivici C., Huen N. Y., Schlom J., Tsang K. Y., Strategies for cancer vaccine development Journal of Biomedicine and Biotechnology 2010 2010
79. Hodi F. S., O'Day S. J., McDermott D. F., Weber R. W., Sosman J. A., Haanen J. B., Gonzalez R., Robert C., Schadendorf D., Hassel J. C., Akerley W., Van Den Eertwegh A. J. M., Lutzky J., Lorigan P., Vaubel J. M., Linette G. P., Hogg D., Ottensmeier C. H., Lebb C., Peschel C., Quirt I., Clark J. I., Wolchok J. D., Weber J. S., Tian J., Yellin M. J., Nichol G. M., Hoos A., Urba W. J., Improved survival with ipilimumab in patients with metastatic melanoma New England Journal of Medicine 2010 363 8 711 723
80. Keilholz U., Martus P., Scheibenbogen C., Immune monitoring of T-cell responses in cancer vaccine development Clinical Cancer Research 2006 12 7 2346s 2352